Barbiturate Addiction & Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Barbiturate Addiction & Treatment Barbiturates are prescribed legally for medical use and produce a wide spectrum of central nervous system depression, from mild sedation to coma. They are used as sedatives, hypnotics, anesthetics and anticonvulsants. The primary differences between barbiturates are related to their effects. Barbiturates are classified as ultra-short, short, intermediate and long-acting. Generally ingested as a pill, barbiturates can also be dissolved and injected. The following barbiturates are available and go by these names: Amobarbital (Amytal), Aprobarbital, Butabarbital (Fiorinal), Hexobarbital (Sombulex), Methylphenobarbital (Mebaral), Pentobarbital (Nembutal), Phenobarbital (Luminal), Secobarbital (Seconal), Talbutal (Lotusate), Thiobarbital, Tuinal (equal proportions of amobarbital and secobarbital) Effects of Barbiturates In moderate amounts, barbiturates produce a state of intoxication that is similar to that of alcohol intoxication. Symptoms can include slurred speech, loss of motor coordination and impaired judgment. Barbiturates can also cause drowsiness, confusion, inability to concentrate, tremors, depressed pulse rate and more. Using barbiturates can lead to addiction and dependency. Lasting/Long-Term Effects Barbiturate users can rapidly develop both a physical and psychological tolerance over time, depending upon dose, frequency and duration of use. With the development of a tolerance for barbiturates, users are at greater risk for overdose, as the margin of safety between an effective dose and a lethal dose becomes narrow over time. This can lead to coma and/or death. Detox/Rehab Due to the fact that barbiturates are legally prescribed to many people, it can be difficult for the user to make the decision to enter treatment. Because the drug is legally prescribed, addicts will often justify the use. .

Copy Link

Recommended publications

Quest Diagnostics Prescription Drug Monitoring Reference Guide
Clinical Drug Monitoring Reference Guide Clinical Drug Monitoring Test List with Test Codes Drug Class P P,D,M P,D D,M D Drug Class P P,D,M P,D D,M D Drug Class P P,D,M P,D D,M D Alcohol Metabolites 90079 16910 92142 16217 Cocaine Metabolite 92225 70248 16888 90082 16916 Naltrexone 93753 Amphetamines 92222 70245 16885 70209 16913 Eszopiclone 91251 Opiates 92230 18991 16891 70237* 16298* Amphetamines Fentanyl 36278 36279 36280 18996 16900 Oxycodone 92231 18992 16892 70238 16920 91590 91589 92484 92483 with Reflex d/l Isomers Gabapentin 70205 16904 Phencyclidine 92232 18993 16893 90083 16921 Antidepressants (urine) 94032 Heroin Metabolite 92226 90081 16911 90333 90329 Pregabalin 70208 16908 Antidepressants (serum) 94031 Marijuana Metabolite 92227 18989 16889 70233 16917 Propoxyphene 92233 18995 16894 70239 16922 Antipsychotics (urine) 94528 MDMA/MDA 92228 90078 16909 90334 90331 Synthetic Cannabinoids 93027 Antipsychotics (serum) 94529 Meperidine 70206 16905 Synthetic Stimulants 90322 Barbiturates 92223 70246 16886 70230 16912 Methadone Metabolite 92229 18990 16890 70234 16918 Tapentadol 90244 90243 Benzodiazepines 92224 70247 16887 70231 16914 Methamphetamine Tramadol 70207 16906 90319 Buprenorphine 16207 70249 16901 18998 16213 d/l Isomers Tricyclic Antidepressants 70204 16903 Buprenorphine 93093 93094 Methylphenidate 90247 90246 with Naloxone Zolpidem 91258 Mitragynine 39241 39240 Carisoprodol 18999 16902 *Includes oxycodone drug class Test Profiles Profile Name Base Profile Profile 1 Profile 2 Profile 3 Profile 4 Profile 5 Profile 6
[Show full text]
Properties and Units in Clinical Pharmacology and Toxicology
Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
[Show full text]
Controlled Substances Included. [M.S.A
1998 PUBLIC AND LOCAL ACTS [No. 319] (HB 4065) AN ACT to amend 1978 PA 368, entitled “An act to protect and promote the public health; to codify, revise, consolidate, classify, and add to the laws relating to public health; to provide for the prevention and control of diseases and disabilities; to provide for the classification, administration, regulation, financing, and maintenance of personal, environ- mental, and other health services and activities; to create or continue, and prescribe the powers and duties of, departments, boards, commissions, councils, committees, task forces, and other agencies; to prescribe the powers and duties of governmental entities and officials; to regulate occupations, facilities, and agencies affecting the public health; to regulate health maintenance organizations and certain third party administrators and insurers; to provide for the imposition of a regulatory fee; to promote the efficient and economical delivery of health care services, to provide for the appropriate utilization of health care facilities and services, and to provide for the closure of hospitals or consolidation of hospitals or services; to provide for the collection and use of data and information; to provide for the transfer of property; to provide certain immunity from liability; to regulate and prohibit the sale and offering for sale of drug paraphernalia under certain circumstances; to provide for penalties and remedies; to provide for sanctions for violations of this act and local ordinances; to repeal certain acts and parts of acts; to repeal certain parts of this act; and to repeal certain parts of this act on specific dates,” by amending sections 7218 and 7401 (MCL 333.7218 and 333.7401), section 7401 as amended by 1996 PA 249, and by adding section 7401a.
[Show full text]
Central Valley Toxicology Drug List
Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
[Show full text]
Highlights of This Issue
THURSDAY, OCTOBER 4, 1973 WASHINGTON, D.C. HIGHLIGHTS OF THIS ISSUE This listing does not affect the legal status of any document published in this issue. Detailed table of contents appears inside. ECONOMIC STABILIZATION— CLC Phase IV pay and price regulations for certain reg istered, practical, and trained nurses (2 documents); effective 10—1—73....................... ........................ 27528, 27529 CLC allows Phase IV price increases for rubber tire and tube products; effective 10—8—73............................. ....... 27528 October 4, 1973— -Pages 27501-27574 METHAQUALONE— Justice Department classifies as Schedule II controlled substance; effective 10—4—73 27516 ARTISTS' PAINTS AND SUPPLIES— Consumer Product Safety Commission exempts from lead content restric tions; effective 12—3—73...-......... ........................................ 27514 DEFENSE CONTRACTS— Cost Amounting Standards Board extends disclosure statement filing requirements; effective 4— 1—74............................. ....................................... 27507 PUBLIC ASSISTANCE— HEW proposal on determin ing paternity of children receiving aid; comments by 1 1 -5 -7 3 ............................................ -. ............ : ........ 27530 SUGAR— USDA declares and reprorates 1973 quota deficits for Hawaii and Peru................... .................... ........................ 27509 USDA requires no proportionate shares for 1974 sugarbeet crop..--....................... ..............."...................... — 27510 PEANUTS— USDA proposes 1974
[Show full text]
Drug Detection Time Window Chart
Chesapeake Toxicology Resources Drug Detection Windows Updated as of December, 15th 2014 The length of time that the presence of drugs of abuse in the body can be detected is an important factor in drug screening. The chart below outlines approximate duration times. When interpreting the duration for the presence of drugs of abuse in the body, you must take into consideration variables including the body's metabolism, the subject's physical condition, overall body ﬂuid balance, state of hydration and frequency of usage. Amphetamines Drug Name Metabolite Detection Window Prescription Names Amphetamine 3-5 Days Adderall, Adderall XR, Dexedrine, Spansule, DextroStat MDA 2-5 Days Tenamfetamine MDMA MDA 1-3 Days Adam, Ecstacy Methamphetamine Amphetamine 3-5 Days Desoxyn, Desoxyn Gradument Anti-epileptics Drug Name Metabolite Detection Window Prescription Names Gabapentin 1-5 Days Neurontin, Nupentin, Fanatrex, Gabarone, Gralise Pregablin 1-4 Days Lyrica CHESAPEAKE TOXICOLOGY RESOURCES- DRUG DETECTION TIMETABLE !1 Barbiturates Drug Name Metabolite Detection Window Prescription Names Amobarbital 2-10 Days Amytal, Amylobarbiton, Tuinal Butalbital 4-6 Days Axocet, Axotal, Bucet, Bupap, Butex Forte, Cephadyn, Dolgic, Esgic, Esgic-Plus, Fioricet, Fiorinal, Fiormor, Fiortal, Fortabs, Laniroif, Margesic, Marten-Tab, Medigesic, Phrenilin, Phrenilin Forte, Repan, Sedapap, Tencon, Triad Pentobarbital 2-10 Days Euthasol, Nembutal , Nembutal Sodium, Pentasol Phenobarbital Up to 16 days Antrocol, Barbidonna, Barbita, Bellacane, Bellatal, Bellergal-S, Chardonna-2,
[Show full text]
124.210 Schedule IV — Substances Included. 1
1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
[Show full text]
DOCUMENT RESUME ED 300 697 CG 021 192 AUTHOR Gougelet, Robert M.; Nelson, E. Don TITLE Alcohol and Other Chemicals. Adolescent A
DOCUMENT RESUME ED 300 697 CG 021 192 AUTHOR Gougelet, Robert M.; Nelson, E. Don TITLE Alcohol and Other Chemicals. Adolescent Alcoholism: Recognizing, Intervening, and Treating Series No. 6. INSTITUTION Ohio State Univ., Columbus. Dept. of Family Medicine. SPONS AGENCY Health Resources and Services Administration (DHHS/PHS), Rockville, MD. Bureau of Health Professions. PUB DATE 87 CONTRACT 240-83-0094 NOTE 30p.; For other guides in this series, see CG 021 187-193. AVAILABLE FROMDepartment of Family Medicine, The Ohio State University, Columbus, OH 43210 ($5.00 each, set of seven, $25.00; audiocassette of series, $15.00; set of four videotapes keyed to guides, $165.00 half-inch tape, $225.00 three-quarter inch tape; all orders prepaid). PUB TYPE Guides - Classroom Use - Materials (For Learner) (051) -- Reports - General (140) EDRS PRICE MF01 Plus Plstage. PC Not Available from EDRS. DESCRIPTORS *Adolescents; *Alcoholism; *Clinical Diagnosis; *Drug Use; *Family Problems; Physician Patient Relationship; *Physicians; Substance Abuse; Units of Study ABSTRACT This document is one of seven publications contained in a series of materials for physicians on recognizing, intervening with, and treating adolescent alcoholism. The materials in this unit of study are designed to help the physician know the different classes of drugs, recognize common presenting symptoms of drug overdose, and place use and abuse in context. To do this, drug characteristics and pathophysiological and psychological effects of drugs are examined as they relate to administration,
[Show full text]
Treatment Episode Data Set (TEDS) 2003 - 2013
Treatment Episode Data Set (TEDS) 2003 - 2013 National Admissions to Substance Abuse Treatment Services DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration ACKNOWLEDGMENTS This report was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA), U.S. Department of Health and Human Services (HHS), by Synectics for Management Decisions, Inc. (Synectics), Arlington, Virginia. Work by Synectics was performed under Task Order HHSS283200700048I/HHSS28342001T, Reference No. 283-07-4803 (Cathie Alderks, Task Order Officer). PUBLIC DOMAIN NOTICE All material appearing in this report is in the public domain and may be reproduced or copied without permission from SAMHSA. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, U.S. Department of Health and Human Services. RECOMMENDED CITATION Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2003-2013. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-75, HHS Publication No. (SMA) 15-4934. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015. ELECTRONIC ACCESS AND COPIES OF PUBLICATION This publication may be downloaded or ordered at store.samhsa.gov. Or call SAMHSA at 1-877-SAMHSA-7 (1-877-726-4727) (English and Español). ORIGINATING OFFICE Center for Behavioral Health Statistics and Quality Substance Abuse and Mental Health Services Administration 1 Choke Cherry Road, Room 2-1084 Rockville, Maryland 20857 December 2015 ii TABLE OF CONTENTS List of Tables ...................................................................................................................................v List of Figures ..............................................................................................................................
[Show full text]
Effects of Chronic Treatment with Testosterone Propionate on Aggression and Hormonal Levels in Intact Male Mice
Psychoneuroendocrinology, Vol. 23, No. 3, pp. 275–293, 1998 © 1998 Elsevier Science Ltd. All rights reserved Printed in Great Britain 0306-4530/98 $19.00+.00 PII: S0306-4530(97)00005-5 EFFECTS OF CHRONIC TREATMENT WITH TESTOSTERONE PROPIONATE ON AGGRESSION AND HORMONAL LEVELS IN INTACT MALE MICE S. Martıńez-Sanchis, A. Salvador, L. Moya-Albiol, E. Gonza´lez-Bono and V. M. Simoń Area de Psicobiologıá, Facultad de Psicologıá, Universitat de Vale`ncia, Avenida Blasco Iban˜ez n° 21, Apartado 22109, 46071 Valencia, Spain (Recei6ed 31 January 1997; in final form 22 No6ember 1997) SUMMARY Effects of testosterone propionate, an anabolic-androgenic steroid (AAS), on aggression in gonadally intact male mice were examined. Animals were given weekly injections of 3.75, 7.5, 15, and 30 mg/kg of drug or sesame oil for 10 weeks. During the last 3 weeks, behavioral tests were conducted and at the end of the experiment, body, liver and testes weight and hormonal data were collected. The treatment had minimal behavioral and endocrine effects. It resulted in shorter latencies of ‘threat’ only in the last agonistic encounter, increases in testosterone levels and decreases in testes weight in a non-linear dose-dependant way. The action of the treatment was different on threat and attack, the latter being unaffected. The behavioral effects in the total sample were only found in aggressive animals selected on the basis of their latency of attack in the first encounter. © 1998 Elsevier Science Ltd. All rights reserved. Keywords—AAS; Testosterone; Corticosterone; Aggression; Intact male mice; Individual differences.
[Show full text]
Introduced B.,Byhansen, 16
LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
[Show full text]
Outline for Controlled Substances Program
Environmental Health and Safety Controlled Substances Program Date of Issuance: Review Date: 10/1/2019 (no changes) 10/01/2018 Revision Number: Initial Prepared by: EH&S Table of Contents HEADINGS Introduction Applicability Responsibilities Registration Requirements Authorized Use Ordering/Purchasing Administering and Dispensing Inventory Procedures (Continuing Records) Security Disposal FORMS: Registering or renewing a DEA or state license (CMU) Controlled Substances Authorized users list (CMU) Employee questionnaire for those with access to controlled substances (CMU) Record of Form 222 use (Order form) (CMU) Records of Controlled Substance Purchases (CMU) Record of Controlled Substance Administering and dispensing (CMU) Controlled Substance Physical Inventory (CMU) DEA Registration of Persons doing research or analysis (Form 225) DEA Registration of Dispensers (Form 224) DEA Registration Instructional (Form 224 and 226 to renew) DEA Report of loss or theft (Form 106) DEA Report of drugs surrendered (From 41) DEA SCHEDULES: Schedule I Schedule II Schedule III Schedule IV Schedule V INTRODUCTION State and Federal regulations have been promulgated concerning the use and handling of US Department of Justice Drug Enforcement Administration (DEA) controlled substances. These regulations are in place to address materials which are or have the potential to be addictive or habit forming. These substances have been categorized into “schedules” that have been created by the DEA to reflect their level of concern. The “Carnegie Mellon University DEA Controlled Substances Program” is intended to ensure that Carnegie Mellon University is in compliance with our regulatory requirements. Required activities under the DEA include: 1. Registration of your work with the DEA and with Carnegie Mellon’s Department of Environmental Health and Safety (EH&S).
[Show full text]